Company Profile
TSH Biopharm Corporation develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping.
Its portfolio also includes AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients, AlphaLiquid 100, a liquid biopsy test designed for patients with advanced solid cancers, and AlphaLiquid HRR, AlphaSolid, and AlphaSolid HRR, a tissue biopsy test designed for patients with advanced solid cancers. Founded in 2000, the company is headquartered in Taipei, Taiwan. TSH Biopharm Corporation Limited operates as a subsidiary of TTY Biopharm Company Limited.